Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD

被引:30
|
作者
Sun, D-Q [1 ,2 ]
Ye, F-Z [3 ,4 ]
Kani, H. T. [5 ]
Yang, J-R [6 ]
Zheng, K., I [3 ]
Zhang, H-Y [7 ]
Targher, G. [8 ,9 ]
Byrne, C. D. [10 ]
Chen, Y-P [3 ,11 ,13 ]
Yuan, W-J [2 ]
Yilmaz, Y. [5 ,12 ]
Zheng, M-H [3 ,11 ]
机构
[1] Nanjing Med Univ, Affiliated Wuxi 2 Peoples Hosp, Dept Nephrol, Wuxi, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Shanghai Gen Hosp, Dept Nephrol, Shanghai, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 1, NAFLD Res Ctr, Dept Hepatol, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[4] Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou, Peoples R China
[5] Marmara Univ, Sch Med, Dept Gastroenterol, TR-34662 Istanbul, Turkey
[6] Wenzhou Med Univ, Affiliated Hosp 1, Dept Clin Lab, Wenzhou, Peoples R China
[7] Sun Yat Sen Univ, Sch Biomed Engn, Guangzhou, Peoples R China
[8] Univ Verona, Dept Med, Div Endocrinol Diabet & Metab, Verona, Italy
[9] Azienda Osped Univ Integrata Verona, Verona, Italy
[10] Univ Hosp Southampton, Southampton Gen Hosp, Southampton Natl Inst Hlth Res, Biomed Res Ctr, Southampton, Hants, England
[11] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
[12] Marmara Univ, Inst Gastroenterol, Istanbul, Turkey
[13] Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Early kidney dysfunction; Liver fibrosis; Liver stiffness measurement; Non-alcoholic fatty liver disease; INSULIN-RESISTANCE; DISEASE; RISK; MICROALBUMINURIA; STEATOHEPATITIS; STRESS;
D O I
10.1016/j.diabet.2019.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. - The association between Liver fibrosis (LF), as assessed by either histology or Liver stiffness measurement (LSM), and the presence of Early kidney dysfunction (EKD) was investigated in this study, as was also the diagnostic performance of LSM for identifying the presence of EKD in patients with Nonalcoholic fatty liver disease (NAFLD). Materials and methods. - A total of 214 adults with non-cirrhotic biopsy-proven NAFLD were recruited from two independent medical centres. Their histological stage of LF was quantified using Brunt's criteria. Vibration-controlled Transient elastography (TE), using M-p robe ( Fib roScan (R)) ultrasound, was performed in 154 patients and defined as significant when LSM was >= 8.0 kPa. EKD was defined as the presence of microalbuminuria with an estimated glomerular filtration rate >= 60 mL/min/1.73 m(2). Logistic regression modelling was used to estimate the likelihood of having EKD with NAFLD (LSM-EKD model). Results. - The prevalence of EKD was higher in patients with vs without LF on histology (22.14% vs 4.82%, respectively; P < 0.001) and, similarly, EKD prevalence was higher in patients with LSM >= 8.0 kPa vs LSM < 8.0 kPa (23.81% vs 6.59%, respectively; P < 0.05). The area under the ROC curve of the LSM-EKD model for identifying EKD was 0.80 (95% CI: 0.72-0.89). LF detected by either method was associated with EKD independently of established renal risk factors and potential confounders. Conclusion. - LF was independently associated with EKD in patients with biopsy-proven NAFLD. Thus, TE-measured LSM, a widely used technique for quantifying LF, can accurately identify those patients with NAFLD who are at risk of having EKD. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:288 / 295
页数:8
相关论文
共 50 条
  • [41] Carriage of CYP2E1rs2070673:A is associated with higher prevalence of non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease
    Ma, Hong-Lei
    Chen, Sui-Dan
    Zheng, Kenneth I.
    Yu, Yue
    Wang, Xin-Xin
    Tang, Liangjie
    Li, Gang
    Rios, Rafael
    Huang, Ou-Yang
    Zheng, Xiao-Yong
    Xu, Ren-Ai
    Targher, Giovanni
    Byrne, Chris
    Wang, Xiaodong
    Chen, Yong-Ping
    Zheng, Ming-Hua
    JOURNAL OF HEPATOLOGY, 2021, 75 : S538 - S538
  • [42] REDUCTIONS IN LIFETIME RISKS OF LIVER-RELATED MORBIDITY AND MORTALITY ASSOCIATED WITH NOVEL DIRECT-ACTING ANTIVIRAL REGIMENS RECOMMENDED FOR TREATING GENOTYPE 4 NON-CIRRHOTIC HEPATITIS C PATIENTS IN THE UNITED STATES
    Saab, S.
    Parise, H.
    Virabhak, S.
    Wang, A.
    Marx, S.
    Johnson, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S743 - S744
  • [43] Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
    George, Jacob
    Newsome, Philip N.
    Bugianesi, Elisabetta
    Ratziu, Vlad
    Rinella, Mary E.
    Roden, Michael
    Engebretsen, Kristiane A.
    Kliers, Iris
    Ostergaard, Laura
    Vanni, Denise
    Zacho, Jeppe
    Sanyal, Arun J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 72 - 73
  • [44] Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
    Newsome, Philip N.
    Bugianesi, Elisabetta
    Ratziu, Vlad
    Rinella, Mary E.
    Roden, Michael
    Engebretsen, Kristiane A.
    Kliers, Iris
    Ostergaard, Laura
    Vanni, Denise
    Zacho, Jeppe
    Sanyal, Arun J.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S606 - S607
  • [45] In Female Patients with Non-alcoholic Fatty Liver Disease (NAFLD), Presence of Type 2 Diabetes (DM) and Chronic Kidney Disease (CKD) are Independently Associated with the Risk of Mortality
    Stepanova, Maria
    de Avila, Leyla
    Birerdinc, Aybike
    Noor, Bashir
    Badoe, Nina
    Younossi, Zobair M.
    HEPATOLOGY, 2015, 62 : 1282A - 1283A
  • [46] Letter: Assessing the prognostic value of agile 3+and agile 4 scores in predicting chronic kidney disease development in patients with metabolic dysfunction-associated steatotic liver disease
    Qin, Zhenzhi
    Xu, Yan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1633 - 1634
  • [47] PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) HAVE SIMILAR CLINICAL, NON-INVASIVE TESTS ( NITS) AND PATIENT-REPORTED OUTCOMES (PROS) PROFILE
    Younossi, Zobair
    Yilmaz, Yusuf
    Yu, Ling-Lung
    Isakov, Vasily
    Fernandez, Marlen Ivon Castellanos
    Wong, Vincent
    Eguchi, Yuichiro
    Romero-Gomez, Manuel
    Duseja, Ajay
    Bugianesi, Elisabetta
    Chan, Wah Kheong
    Alswat, Khalid
    Hamid, Saeed
    Singal, Ashwani
    Fan, Jian-Gao
    Papatheodoridis, George
    Gordon, Stuart
    El-Kassas, Mohamed
    Younes, Ziad
    Roberts, Stuart
    Mendez-Sanchez, Nahum Nahum
    Keklikkiran, Caglayan
    Ahmed, Aijaz
    Lam, Brian
    Nader, Fatema
    Henry, Linda
    Stepanova, Maria
    Alqahtani, Saleh
    HEPATOLOGY, 2024, 80
  • [48] Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): A cross-sectional observational study
    Chung, Nien-Ting
    Hsu, Chiann-Yi
    Shih, Nai-Chen
    Wu, Jia-Jyun
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2025, 35 (01)
  • [49] HIGHER INTRA-OPERATIVE PEAK LACTATE VALUE MAY BE ASSOCIATED WITH PROLONGED HEMODIALYSIS REQUIREMENT AFTER LIVER TRANSPLANT ALONE IN PATIENTS WITH PRE- TRANSPLANT KIDNEY DYSFUNCTION
    Miyake, Katsunori
    Al-Juburi, Saleh
    Young, Kathleen
    Chau, Lucy Ching
    Kitajima, Toshihiro
    Wickramaratne, Nikuwa
    Nassar, Ahmed
    Yoshida, Atsushi
    Moonka, Dilip
    Venkat, Deepak
    Abouljoud, Marwan S.
    Nagai, Shunji
    HEPATOLOGY, 2023, 78 : S314 - S315
  • [50] Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD)
    Charu, Vivek
    Kwong, Allison
    Mannalithara, Ajitha
    Yoon, Eileen
    Jun, Dae Won
    Kim, W. Ray
    JOURNAL OF HEPATOLOGY, 2022, 77 : S462 - S462